Topics

J.P. Morgan Notebook Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And More

20:34 EST 15 Jan 2020 | SCRIP

Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: AbbVie's Skyrizi takes psoriasis lead, Amarin goes it alone, Viatris...

      

Related Stories

 

Original Article: J.P. Morgan Notebook Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And More

NEXT ARTICLE

More From BioPortfolio on "J.P. Morgan Notebook Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And More"

Quick Search

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...